In this study, we showed that MAP4K4 is commonly upregulated in human hepatocellular carcinoma (HCC) specimens compared to adjacent nontumor liver tissues, and this upregulation is significantly associated with tumor size, tumor grade and intrahepatic metastasis. Survival analyses have demonstrated that high MAP4K4 expression serves as an independent predictor of poor prognosis in HCC patients. Furthermore, multiple tumor progression-related signaling pathways including JNK, nuclear factor-kappa B, and toll-like receptors were repressed by MAP4K4 downregulation.
Introduction
Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality worldwide, with more than 600,000 new cases diagnosed annually (1) . The most frequent risk factors for HCC include chronic viral hepatitis, alcohol abuse, and dietary exposure to aflatoxins (2) (3) (4) (5) . Early HCC is potentially curable by resection, liver transplantation, or percutaneous treatment, and 5-year survival rates of up to 60 to 70% can be achieved in well-selected patients (6) . Unfortunately, most patients are diagnosed at the advanced stage in developing countries where regular tumor surveillance has not been implemented and therefore precluded from the curative treatments. For patients with advanced HCC, the multikinase inhibitor sorafenib is available as a systemic therapy, offering a significant survival advantage (7, 8) .
Despite significant progress, advanced HCC still remains incurable. The identification of molecular markers and pathways that contribute to the aggressive phenotype of HCC is obviously essential for development of more effective, targeted therapies.
Mitogen-activated protein kinases (MAPKs) are a family of conserved serine/threonine protein kinases that function to transmit extracellular signals into the cytoplasm. The different MAPKs can be divided into three main subgroups, i.e. the extracellular signal-regulated protein kinase (ERK), c-Jun N-terminal kinase/stress-activated protein kinases (JNK/SAPK) and p38 (9) . MAPKs are commonly activated through phosphorylation cascades, and subsequently phosphorylate a number of effectors that contribute to the regulation of diverse cellular events, including differentiation (10, 11) , proliferation (12, 13) , survival (14) , migration (15) , and invasion (16) . MAPK kinase kinase kinase isoform 4 (MAP4K4), a germinal centre protein kinase that belongs to the mammalian STE20/MAP4K
family, is implicated in the activation of the JNK/SAPK pathway (17, 18) . Recent studies (17, 19) have documented that MAP4K4 is overexpressed in many types of human cancer. The prognostic significance of MAP4K4 overexpression has been demonstrated in patients with stage II pancreatic ductal adenocarcinoma (PDA) (19) .
Silencing of MAP4K4 using small interfering RNAs (siRNAs) causes reduced tumor cell motility in ovarian carcinoma-derived cell line, SKOV-3 (17 The clinicopathologic characteristics of both the study cohorts are summarized in Supplementary Table 1 . In the following, we focused on the description of the patients of Cohort B, who were selected for further elucidation of the clinical significance of MAP4K4 expression. Of the 400 studied patients, there were 305 (76%) and 245 (61%) patients positive for hepatitis B surface antigens (HBsAg) and for hepatitis B e antigen (HBeAg), respectively. Liver cirrhosis was found in 275 (69%) cases. Seventy-eight patients (20%) had alcohol abuse and 12 (3%) had non-alcoholic steatohepatitis. All the subjects were negative for hepatitis C virus (HCV) RNA. Patients with large (>2 cm) tumors comprised 86%, and intrahepatic metastasis was seen in 62% patients. Tumors were staged according to the 2002 tumor-node-metastasis (TNM) classification system (20) . A total of 85 (21%) MAP4K4-H group compared to the MAP4K4-L group (22) . Given the possibility of imbalance between the two groups, some more patients were included in the present study. Significance between controls and treatment samples was calculated by
Student's t test. The relationship between MAP4K4 protein expression and clinicopathologic features of HCC was analyzed using the Pearson χ 2 test. Since early tumor recurrence (i.e. recurrence within 2 years after surgery) occurs more likely due to primary tumor dissemination rather than de novo carcinogenesis arisen from cirrhotic liver (23) , in this study we used early tumor recurrence as an endpoint.
Time to recurrence was calculated from the date of surgery to the date of first documented recurrence; patients without recurrence within 2 years were censored.
Another primary endpoint was overall survival, which was calculated from the date of diagnosis to the date of death or the date of last follow-up (if death did not occur).
Overall survival and time to recurrence were calculated using the Kaplan-Meier method. The differences between patient groups were analyzed using the log-rank test. The prognostic significance of clinicopathologic factors was determined using univariate Cox regression analysis. Multivariate survival analysis was done with a Cox proportional hazards model. Statistical significance was assumed for a 2-tailed P value less than 0.05. Surrounding non-neoplastic liver tissues displayed less cytoplasmic staining for MAP4K4, while HCC tissues showed variable proportions of MAP4K4-positive cells that gradually increased with the grades of differentiation from well differentiated to poorly differentiated (Fig. 1B) . Additionally, we also analyzed the MAP4K4 expression in several human HCC cell lines (HepG2, Huh7, Hep3B and SMMU7721). MAP4K4 was found to be expressed at higher levels in HepG2 and Hep3B than in Huh7 and SMMU7721 cells (Fig. 1C) (Fig. 1D) . The early recurrence rate was significantly (P=0.0001) higher in the MAP4K4-H group than in the MAP4K4-L group (Fig. 1D) The multivariate survival analysis revealed that MAP4K4 expression was a predictor of overall and early recurrence (P = 0.019 and 0.018, respectively) independent of serum HBsAg and HBeAg status, intrahepatic metastasis, as well as tumor stage (Table 3) . Having identified MAP4K4 as a potential oncogene in HCC, we next sought to investigate its downstream signaling pathways using the human TLR signaling pathway PCR array. This array was chosen because it can profile the expression of multiple genes related to the TLR, NFκB, and JNK/p38 signaling pathways, which contribute to HCC progression (24) (25) (26) (27) . The most differentially expressed genes whose expression changed 2 fold or more in MAP4K4-A1-producing HepG2 cells compared to control shRNA-expressing cells were summarized in Supplementary to the control cells (Fig. 3C) . In contrast, the phosphorylation levels of ERK1/2 or p38 MAPK were comparable between the MAP4K4-A1-and control shRNA-expressing cells, suggesting that MAP4K4 selectively regulates the JNK rather than ERK1/2 or p38 MAPK pathway. Additionally, we found that the expression of TLR5, TLR4, MyD88, and TRAF6 was also downregulated in MAP4K4-A1-transfected cells (Fig. 3C) . These data suggest that in HCC, multiple
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with worse prognosis and to serve as a prognostic marker for stage II pancreatic ductal adenocarcinomas (19) . These findings imply an oncogenic role for MAP4K4; however, little is known about its expression pattern and biological significance in to apoptosis in vitro and in vivo (24, 25, 29, 30) . Third, our data and previous studies (17, 18) show that MAP4K4 regulates the JNK activation. In contrast to JNK, the other two MAPK pathways, ERK and p38, are not affected by MAP4K4 inhibition, implying a unique mediator role for JNK in MAP4K4 signaling transduction.
Besides JNK, another two MAP4K4-repressed pathways, TLR and NFκB, are also involved in tumorigenesis (26, 27) . NFκB has been shown to link inflammation to cancer (31) (32) (33) . In different contexts, NFκB displays opposing roles in Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval.
Significant P values are marked in bold. 
